Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Durata Therapeutics, Inc.

http://www.duratatherapeutics.com/

Latest From Durata Therapeutics, Inc.

Stock Watch: How The Pandemic Impact On Pharma’s Value Chain Is Mutating

From clinical trials to in-person sales calls, the pharmaceutical value chain has been tested by the COVID-19 pandemic, but has held up. Nevertheless, recent friction within this chain may be more than a passing irritation.

Distribution Coronavirus COVID-19

Stock Watch: Donanemab Provides Cover For Lilly’s Second-Quarter Insulin Challenge

Lilly’s second-quarter earnings announcement relegated its core business in favor of its experimental Alzheimer’s disease drug. This diverted attention away from competitive reimbursement challenges that may be affecting its insulin business.

Stock Watch Sales & Earnings

CMS Medicare Center Director Seshamani Will Steer Coverage Decision On Aduhelm

Meena Seshamani served in the Obama Administration as head of the health reform office within the Health and Human Services Department.

Leadership Medicare

First Lucentis Biosimilar Among Drugs Awaiting Verdict On EU Approval Filings

Sponsors of several new medicines, including the first ever CAR-T for multiple myeloma, will find out this week if their products are on track to get EU marketing authorizations. Also, three sponsors might be asked to address outstanding issues about their products in the final stages of review.

Europe Drug Review
See All

Company Information

UsernamePublicRestriction

Register